XORTX Therapeutics Inc.

Healthcare · Biotechnology · Canada

Last price 1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.82M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th...